Show simple item record

dc.contributor.authorKepiro, Ibolya Een
dc.contributor.authorMarzuoli, Ireneen
dc.contributor.authorHammond, Katharineen
dc.contributor.authorBa, Xiaoliangen
dc.contributor.authorLewis, Helenen
dc.contributor.authorShaw, Michaelen
dc.contributor.authorGunnoo, Smita Ben
dc.contributor.authorDe Santis, Emilianaen
dc.contributor.authorŁapińska, Urszulaen
dc.contributor.authorPagliara, Stefanoen
dc.contributor.authorHolmes, Marken
dc.contributor.authorLorenz, Christian Den
dc.contributor.authorHoogenboom, Bart Wen
dc.contributor.authorFraternali, Francaen
dc.contributor.authorRyadnov, Maxim Gen
dc.date.accessioned2020-01-24T00:30:54Z
dc.date.available2020-01-24T00:30:54Z
dc.date.issued2019-12-05en
dc.identifier.issn1936-0851
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/301228
dc.description.abstractAntimicrobial resistance stimulates the search for antimicrobial forms that may be less subject to acquired resistance. Here we report a conceptual design of protein pseudocapsids exhibiting a broad spectrum of antimicrobial activities. Unlike conventional antibiotics, these agents are effective against phenotypic bacterial variants, while clearing "superbugs" in vivo without toxicity. The design adopts an icosahedral architecture that is polymorphic in size, but not in shape, and that is available in both l and d epimeric forms. Using a combination of nanoscale and single-cell imaging we demonstrate that such pseudocapsids inflict rapid and irreparable damage to bacterial cells. In phospholipid membranes they rapidly convert into nanopores, which remain confined to the binding positions of individual pseudocapsids. This mechanism ensures precisely delivered influxes of high antimicrobial doses, rendering the design a versatile platform for engineering structurally diverse and functionally persistent antimicrobial agents.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEngineering Chirally Blind Protein Pseudocapsids into Antibacterial Persisters.en
dc.typeArticle
prism.publicationDate2019en
prism.publicationNameACS nanoen
dc.identifier.doi10.17863/CAM.48310
dcterms.dateAccepted2019-12-03en
rioxxterms.versionofrecord10.1021/acsnano.9b06814en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-12-05en
dc.contributor.orcidKepiro, Ibolya E [0000-0002-8934-3389]
dc.contributor.orcidMarzuoli, Irene [0000-0001-7536-6144]
dc.contributor.orcidHammond, Katharine [0000-0002-3755-6489]
dc.contributor.orcidBa, Xiaoliang [0000-0002-3882-3585]
dc.contributor.orcidLewis, Helen [0000-0002-9993-0640]
dc.contributor.orcidShaw, Michael [0000-0001-6099-3217]
dc.contributor.orcidGunnoo, Smita B [0000-0002-7435-8377]
dc.contributor.orcidDe Santis, Emiliana [0000-0002-0943-6586]
dc.contributor.orcidŁapińska, Urszula [0000-0003-3593-9248]
dc.contributor.orcidPagliara, Stefano [0000-0001-9796-1956]
dc.contributor.orcidHolmes, Mark [0000-0002-5454-1625]
dc.contributor.orcidLorenz, Christian D [0000-0003-1028-4804]
dc.contributor.orcidHoogenboom, Bart W [0000-0002-8882-4324]
dc.contributor.orcidFraternali, Franca [0000-0002-3143-6574]
dc.contributor.orcidRyadnov, Maxim G [0000-0003-4847-1154]
dc.identifier.eissn1936-086X
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMEDICAL RESEARCH COUNCIL (MR/N002660/1)
pubs.funder-project-idMEDICAL RESEARCH COUNCIL (MR/P007201/1)
pubs.funder-project-idESRC (ES/S000186/1)
pubs.funder-project-idMRC (G1001787)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International